Skip to main content
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1982 Feb;13(2):219–222. doi: 10.1111/j.1365-2125.1982.tb01360.x

Oxprenolol, methyldopa and lipids in diabetes mellitus.

G F Benfield, K R Hunter
PMCID: PMC1402012  PMID: 7037030

Abstract

1 Twelve-week courses of oxprenolol and methyldopa were administered in a randomised, double-blind cross over study to ten insulin dependent hypertensive diabetics. 2 Prior to treatment, and at the end of each period of drug administration, fasting levels of high density lipoprotein, triglycerides, free fatty acids and cholesterol were measured. 3 Neither preparation altered levels of high density lipoprotein and cholesterol, but both drugs significantly reduced the free fatty acids. 4 Whereas oxprenolol did not alter triglyceride levels, methyldopa significantly elevated triglycerides above pre-treatment values. 5 Oxprenolol does not appear to influence lipoprotein fractions affecting the relative risks of coronary heart disease, but methyldopa seems to have potentially detrimental effects of triglyceride levels.

Full text

PDF
219

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. CORNWELL D. G., KRUGER F. A., HAMWI G. J., BROWN J. B. Studies on the characterization of human serum lipoproteins separated by ultracentrifugation in a density gradient. II. Serum lipoproteins in hyperlipemic subjects. Am J Clin Nutr. 1961 Jan-Feb;9:41–54. doi: 10.1093/ajcn/9.1.41. [DOI] [PubMed] [Google Scholar]
  2. Carlson L. A., Böttiger L. E. Ischaemic heart-disease in relation to fasting values of plasma triglycerides and cholesterol. Stockholm prospective study. Lancet. 1972 Apr 22;1(7756):865–868. doi: 10.1016/s0140-6736(72)90738-6. [DOI] [PubMed] [Google Scholar]
  3. Day J. L., Simpson N., Metcalfe J., Page R. L. Metabolic consequences of atenolol and propranolol in treatment of essential hypertension. Br Med J. 1979 Jan 13;1(6156):77–80. doi: 10.1136/bmj.1.6156.77. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Enger S. C., Hjermann I., Foss O. P., Helgeland A., Holme I., Leren P., Norum K. R. High density lipoprotein cholesterol and myocardial infarction or sudden coronary death: a prospective case-control study in middle-aged men of the Oslo study. Artery. 1979 Feb;5(2):170–181. [PubMed] [Google Scholar]
  5. FURMAN R. H., HOWARD R. P., LAKSHMI K., NORCIA L. N. The serum lipids and lipoproteins in normal and hyperlipidemic subjects as determined by preparative ultracentrifugation. Effects of dietary and therapeutic measures. Changes induced by in vitro exposure of serum to sonic forces. Am J Clin Nutr. 1961 Jan-Feb;9:73–102. doi: 10.1093/ajcn/9.1.73. [DOI] [PubMed] [Google Scholar]
  6. Helgeland A., Hjermann I., Leren P., Enger S., Holme I. High-density lipoprotein cholesterol and antihypertensive drugs: the Oslo study. Br Med J. 1978 Aug 5;2(6134):403–403. doi: 10.1136/bmj.2.6134.403. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Lewis B., Mancini M., Mattock M., Chait A., Fraser T. R. Plasma triglyceride and fatty acid metabolism in diabetes mellitus. Eur J Clin Invest. 1972 Nov;2(6):445–453. doi: 10.1111/j.1365-2362.1972.tb00676.x. [DOI] [PubMed] [Google Scholar]
  8. Miller G. J., Miller N. E. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet. 1975 Jan 4;1(7897):16–19. doi: 10.1016/s0140-6736(75)92376-4. [DOI] [PubMed] [Google Scholar]
  9. Pelkonen R., Nikkilä E. A., Koskinen S., Penttinen K., Sarna S. Association of serum lipids and obesity with cardiovascular mortality. Br Med J. 1977 Nov 5;2(6096):1185–1187. doi: 10.1136/bmj.2.6096.1185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Shaw J., England J. D., Hua A. S. Beta-blockers and plasma triglycerides. Br Med J. 1978 Apr 15;1(6118):986–986. doi: 10.1136/bmj.1.6118.986-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Tanaka N., Sakaguchi S., Oshige K., Niimura T., Kanehisa T. Effect of chronic administration of propranolol on lipoprotein composition. Metabolism. 1976 Oct;25(10):1071–1075. doi: 10.1016/0026-0495(76)90014-7. [DOI] [PubMed] [Google Scholar]
  12. Waal-Manning H. J., Simpson F. O. Beta-blockers and lipid metabolism. Br Med J. 1977 Sep 10;2(6088):705–705. doi: 10.1136/bmj.2.6088.705. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES